Success Story: EB-1A Approval Without RFE for a Biomedical Science Researcher with Global Research Impact
Client’s Testimonial:
"Once again, thank you very much for all your effort and guidance in preparing and presenting my case."
On August 6th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Visiting Instructor in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Biomedical Science
Country of Origin: India
State of Residence at the Time of Filing: Illinois
Approval Notice Date: August 6th, 2026
Processing Time: 1 month, 7 days (Premium Processing Upgrade Requested)
Case Summary:
“His remarkable works, active role in the peer review and editorial process, and extensive citation record establish [Client] as a uniquely valuable figure in the field of biomedical science.”
This statement is drawn from a recommendation letter highlighting the client’s leadership in biomedical science, particularly in advanced disease research, experimental modeling, and biomarker development.
The client’s work focuses on disease pathology and biomarker discovery, with an emphasis on complex human diseases, inflammatory and metabolic disorders, and related diagnostic and therapeutic strategies. Holding a Ph.D. in biomedical science, the client was conducting research at a U.S. university at the time of filing, where the client continued studying disease mechanisms, biomarkers, and therapeutic targets.
North America Immigration Law Group (NAILG) prepared the I-140 EB-1A petition by presenting the client’s work as a record of sustained scientific influence, not merely a list of publications. The petition showed that the client had made original contributions of major significance, authored scholarly articles in respected venues, and served as a judge of others’ work through extensive peer-review and editorial activity.
The client’s record included:
- 30 peer-reviewed journal articles, including 7 first-authored or co-first-authored articles
- 40 conference abstracts, including 6 first-authored abstracts
- 1,252 citations to the client’s published work
- At least 160 completed peer reviews for authoritative journals
- 4 recommendation letters from experts in the field, including 3 independent advisory opinions
- Research support from the American Association for the Study of Liver Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Alcohol Abuse and Alcoholism, the Department of Defense Office of the Congressionally Directed Medical Research Programs Grant, the Veterans Administration Biomedical Laboratory Research and Development Grant, and the Indo-French Center for the Promotion of Advanced Research
To demonstrate the client’s significance, we highlighted how independent researchers relied on the client’s findings in later studies involving osteopontin in chronic liver disease, albumin modifications in severe alcoholic hepatitis, iron homeostasis in acute-on-chronic liver failure, disease prognosis, biomarker discovery, inflammation, and translational diagnostic methods. These examples helped show that the client’s research had practical value for scientists working to understand complex disease mechanisms and improve clinical assessment.
The petition also explained the strength of the client’s citation record in context. At least 11 of the client’s papers ranked among the most highly cited Clinical Medicine articles for their publication years, including multiple papers in the top 1% and top 10% citation ranges. This evidence helped demonstrate that the client’s work had received recognition beyond ordinary publication and had been repeatedly relied upon by the field.
By combining publication impact, citation context, peer-review service, editorial roles, funded research, expert letters, and continued U.S. research plans, NAILG demonstrated that the client had sustained acclaim and a level of expertise consistent with the EB-1A standard.
USCIS approved the client’s I-140 EB-1A petition without an RFE after a premium processing upgrade was requested. This approval supports the client’s continued contributions to biomedical science, biomarker discovery, disease prognosis, and therapeutic development in the United States.